0001628280-21-000060.txt : 20210105 0001628280-21-000060.hdr.sgml : 20210105 20210105160327 ACCESSION NUMBER: 0001628280-21-000060 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210102 FILED AS OF DATE: 20210105 DATE AS OF CHANGE: 20210105 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Erlander Mark CENTRAL INDEX KEY: 0001651537 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35558 FILM NUMBER: 21505377 MAIL ADDRESS: STREET 1: C/O TROVAGENE, INC. STREET 2: 11055 FLINTKOTE AVENUE, SUITE A CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cardiff Oncology, Inc. CENTRAL INDEX KEY: 0001213037 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 272004382 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 11055 FLINTKOTE AVENUE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-952-7570 MAIL ADDRESS: STREET 1: 11055 FLINTKOTE AVENUE CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: Trovagene, Inc. DATE OF NAME CHANGE: 20130304 FORMER COMPANY: FORMER CONFORMED NAME: TrovaGene Inc. DATE OF NAME CHANGE: 20110830 FORMER COMPANY: FORMER CONFORMED NAME: XENOMICS INC DATE OF NAME CHANGE: 20040719 4 1 wf-form4_160988059527289.xml FORM 4 X0306 4 2021-01-02 0 0001213037 Cardiff Oncology, Inc. CRDF 0001651537 Erlander Mark C/O CARDIFF ONCOLOGY, INC. 11055 FLINTKOTE AVE SAN DIEGO CA 92121 0 1 0 0 Chief Executive Officer Common Stock 2021-01-02 4 M 0 260 0 A 13629 D Common Stock 2021-01-02 4 F 0 113 0 D 13516 D Restricted Stock Units 2021-01-02 4 M 0 260 0 D Common Stock 260.0 0 D Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On January 4, 2017, the reporting person was granted 1,459 restricted stock units, 261 of which vested on January 2, 2020. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 4, 2017. The reporting person is reporting the withholding by Cardiff Oncology, Inc. of 113 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the delivery of the Converted Common Stock to the reporting person on January 4, 2021. Each restricted stock unit is the economic equivalent of one share of Cardiff Oncology, Inc. common stock. On January 4, 2017, the reporting person was granted 1,459 restricted stock units, 260 of which vested on January 2, 2021. The common stock into which such vested restricted stock units converted on January 2, 2021 is reported in Table I on this Form 4. /s/ Mark Erlander 2021-01-05